Sepsis, October 19 edition

Using LPS-challenged mice and LPS-primed murine and human macrophages, the study found that extracellular L-carnitine activates the pyrin inflammasome after uptake through the high-affinity transporter OCTN2. L-carnitine suppressed mevalonate synthesis, and pyrin and OCTN2 were also required for inflammatory responses to skeletal muscle injury, establishing a previously unrecognized connection between muscle damage, dietary metabolites, and innate inflammation.

Impact: This study identifies a novel molecular pathway connecting extracellular L-carnitine and muscle injury to pyrin inflammasome activation. It advances understanding of sterile inflammation and provides a potential mechanistic target relevant to inflammatory disease and sepsis-associated tissue injury.

Clinical Implications: The findings are not yet practice-changing, but they suggest that OCTN2, L-carnitine handling, mevalonate metabolism, or pyrin inflammasome signaling could become targets for future anti-inflammatory interventions. Translation to human sepsis will require confirmation that this pathway contributes to clinically relevant disease phenotypes.

Future Directions: Future studies should assess this pathway in human sepsis cohorts, determine whether circulating or tissue L-carnitine predicts inflammatory severity, and test selective modulation of OCTN2, mevalonate metabolism, or pyrin signaling in clinically relevant infection and injury models.

This systematic review and meta-analysis included 21 randomized controlled trials involving 3,873 patients with septic shock. Compared with norepinephrine alone, adding vasopressin-receptor agonists was associated with lower mortality at the longest complete follow-up, with trial sequential analysis used to assess random error.

Impact: The analysis addresses a central hemodynamic treatment question using a comparatively large body of randomized evidence. If the mortality signal is robust and applicable across vasopressin-receptor agonists, it could support more consistent adjunctive vasopressor strategies in septic shock.

Clinical Implications: Clinicians may consider vasopressin-receptor agonists as adjuncts to norepinephrine in selected adults with septic shock who require escalating vasopressor support. The findings should be integrated with current guideline recommendations, drug-specific adverse-event profiles, and individual risks such as ischemia or arrhythmia rather than interpreted as justification for routine use in every patient.

Future Directions: Future work should compare individual vasopressin-receptor agonists, identify phenotypes most likely to benefit, clarify ischemic and arrhythmic harms, and conduct prospective comparative-effectiveness trials using standardized timing, dosing, and patient-centered outcomes.

This registered systematic review and meta-analysis synthesized six randomized controlled trials involving 9,743 children with sepsis or septic shock. Balanced salt solutions and normal saline produced similar hospital or 30-day mortality rates (3.5% versus 3.7%; RR 0.97, 95% CI 0.81-1.16), indicating no demonstrated mortality advantage for balanced solutions in this population.

Impact: Fluid selection is a frequent early decision in pediatric sepsis, and practice has increasingly favored balanced solutions based on adult data and concerns about chloride exposure. This large pediatric synthesis, using prospective registration and GRADE assessment, provides an important negative result that may prevent overgeneralization of adult evidence.

Clinical Implications: Both balanced solutions and normal saline remain reasonable isotonic crystalloids for initial pediatric sepsis resuscitation when mortality is the primary consideration. Clinicians should individualize fluid choice according to electrolyte and acid-base status, renal function, local protocols, availability, and other patient-specific factors rather than assuming that balanced solutions improve survival.

Future Directions: Future pediatric trials should standardize fluid dose and timing, stratify by shock phenotype and kidney injury risk, and prioritize patient-centered outcomes including acute kidney injury, electrolyte disturbances, vasopressor exposure, duration of organ support, and neurological outcomes.